These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32712432)

  • 1. Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Chanas-Larue A; Villalpando-Rodriguez GE; Henson ES; Johnston JB; Gibson SB
    Leuk Res; 2020 Sep; 96():106423. PubMed ID: 32712432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosome-Disrupting Agents in Combination with Venetoclax Increase Apoptotic Response in Primary Chronic Lymphocytic Leukemia (CLL) Cells Mediated by Lysosomal Cathepsin D Release and Inhibition of Autophagy.
    Manivannan MS; Yang X; Patel N; Peters A; Johnston JB; Gibson SB
    Cells; 2024 Jun; 13(12):. PubMed ID: 38920669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
    Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
    Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
    Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
    Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
    Sharif-Askari B; Doyon D; Paliouras M; Aloyz R
    Sci Rep; 2019 Jul; 9(1):11069. PubMed ID: 31363127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
    Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
    Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Ayed AO; Parikh SA
    Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.